Innovation Pharmaceuticals (Innovation Pharmaceuticals) EPS (Diluted) : $-0.01 (TTM As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals EPS (Diluted)?

Innovation Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01.

Innovation Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2023 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01.

Innovation Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2023 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was 23.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Innovation Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 43.20% per year. The lowest was -100.00% per year. And the median was -18.60% per year.

Innovation Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Innovation Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals EPS (Diluted) Chart

Innovation Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EPS (Diluted)

Get a 7-Day Free Trial

-0.05

-0.03

-0.04

-0.01

Innovation Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Diluted)	Get a 7-Day Free Trial															-	-	-	-0.01	-

Competitive Comparison of Innovation Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Innovation Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's PE Ratio falls into.

Innovation Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Innovation Pharmaceuticals's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-3.168	-	0)	/	505.768
	=	-0.01

Innovation Pharmaceuticals's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.88	-	0)	/	518.348
	=	-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Innovation Pharmaceuticals (OTCPK:IPIX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Innovation Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website

http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

Executives

Arthur Peter Bertolino	officer: Pres. & Chief Medical Officer	C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness	officer: Vice President	100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin	director	C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor	director	17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter	director	7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich	director, 10 percent owner, officer: Chief Financial Officer	C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon	director, 10 percent owner, officer: President-Chief Scient.Officer	10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans	director, officer: Chief Executive Officer	17 IRVING PLACE, PELHAM NY 10803